glp 1 agonist or antagonist Frontiers Central glucagon-like peptide 1 receptor

Quick look at the key results According to clinical trial investigators, orforglipron: Led to significant weight reduction across all dosing groups Showed greater effects at the highest dose levels Helped lower blood sugar in people with diabetes Supported modest improvements in blood pressure Demonstrated mainly mild to moderate side effects The trial results suggest that the once-daily pill performs competitively with early GLP-1 injection studies

Less motivated

FAQs Q1

Here are the ones that fit the bill so far: Semaglutide: For weight loss, 2.4 mg of semaglutide (compared with 1 mg for diabetes management) is typically administered once weekly

Semaglutide for weight loss: unanswered questions

It is even more significant in Mounjaro (tirzepatide) which will likely be FDA approved by the end of the year for weight loss